Metis Precision Medicine, founded in 2017 as a Benefit Company by Prof Paolo Comoglio, is based in Turin, Italy and develops oncologic therapies. The company is developing a medicine intended to induce clinical remission and prolong patients' lives in selected cases. It holds an IP portfolio related to monoclonal antibodies targeting the Met oncogene. Metis intends to use funds to complete pre-clinical work and finalize the deposit of a new IP. The company raised seed funding to support these pre-clinical efforts and advance its therapeutic program.

Total raised

$1M

Funding rounds

1

Latest round

Seed

Latest activity

Mar 2018